investors & media
NASDAQ: (common stock)
Copyright West LLC. Minimum 15 minutes delayed.
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patientsRead more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 19, 2019-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January: Goldman Sachs 12 th Annual Healthcare CEOs Unscripted: A View from the Top, Thursday,Read more
Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 CAMBRIDGE, Mass. , & PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 9, 2019-- bluebird bio, Inc.Read more